{"filings":[{"id":92441,"accession_number":"0001367644-26-000059","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).","Smallpox MCM revenue down 40% to $64.2M; Anthrax MCM down 55% to $21.6M.","Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) in Q1 2025.","FY 2026 adjusted net income guidance raised to $45-65M (from $25-45M); FY 2026 adjusted EBITDA guidance raised to $155-175M (from $135-155M).","Completed debt refinancing with $150M term loan; secured over $200M in new U.S./Canada government contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":156100000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92440,"accession_number":"0001367644-26-000051","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders approve increase in Emergent BioSolutions' stock incentive plan by 5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to stock incentive plan adding 5M shares, total reserve now 36,208,561 shares.","Director nominees elected: Dayal, Fowler, Harsanyi, Papa; each received >93% of votes cast (excluding broker non-votes).","Advisory say-on-pay approved with 58.4% support; 18.2M for, 12.0M against, 0.9M abstain.","Ratification of Ernst & Young as auditor approved with 96.7% of votes cast.","Plan amendment changes full-value award counting ratio to 1.0 from 1.6 per share for grants after April 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92439,"accession_number":"0001367644-26-000038","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","1.02","3.02","2.03","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions closes $150M Term Loan with OrbiMed, extends maturities, cuts interest expense 200 bps","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $150M Term Loan with OrbiMed matures April 2031, replaces prior $150M OHA facility; ABL reduced to $50M.","Interest expense on Term Loan reduced by 200 basis points annually (Term SOFR + 6.25%, floor 3%).","Delayed draw term loan of $75M available for 24 months for acquisitions/growth capex.","Maturities extended to April 2031 from August 2029 (Term Loan) and Sept 2029 (ABL).","Company expects lower interest expense and enhanced flexibility to support transformation plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103283,"accession_number":"0001367644-26-000019","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions appoints John D. Fowler, Jr. to board of directors effective March 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fowler appointed as Class II director and will serve on the Audit and Finance Committee.","Receives initial RSU grant valued at $270,000 vesting in three equal annual installments.","Annual compensation: $70,000 cash retainer, $15,000 committee fee, $270,000 equity award (prorated first year).","Chairman Zsolt Harsanyi states Fowler's experience will support the company's ongoing turnaround and transformation.","Fowler brings 30+ years in healthcare and finance, including senior roles at Wells Fargo, Deutsche Bank, and JPMorgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103282,"accession_number":"0001367644-26-000012","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.","Q4 2025 net loss $54.6M ($1.04 loss per diluted share), vs Q4 2024 loss $31.3M.","Full year 2025 net income $52.6M ($0.93 diluted EPS), vs prior year net loss $190.6M.","Adjusted EBITDA for FY2025 $205.0M, up 12% from $183.1M in 2024.","FY2026 guidance: revenues $720-760M, adjusted net income $25-45M, adjusted EBITDA $135-155M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":742900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103281,"accession_number":"0001193125-26-013061","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions CEO presents at J.P. Morgan Healthcare Conference; no new data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Joe Papa presented at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.","Investor slides furnished as Exhibit 99.1 contain no specific financial results or guidance updates.","No material business or operational changes disclosed in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103280,"accession_number":"0001367644-26-000003","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions voluntarily prepays $100M of term loan; total debt reduced by $275M since 2023","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Voluntary prepayment of $100M on term loan using cash on hand in late December 2025.","Pro forma gross debt reduced to $593M, a 32% decline from $868M since the transformation plan began in 2023.","CEO Joe Papa says the prepayment improves financial flexibility and supports long-term growth initiatives.","Company to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119539,"accession_number":"0001367644-25-000207","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.","Raxibacumab is a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.","Approval supports multi-year turnaround strategy to consolidate manufacturing in Winnipeg and Lansing.","Winnipeg facility has over 45 years experience in commercial therapeutics manufacturing.","CEO Joe Papa says this regulatory action advances flexible, streamlined manufacturing network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119538,"accession_number":"0001367644-25-000204","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions director Louis W. Sullivan to retire Nov 14 after 19 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sullivan notified board of retirement effective Nov 14, 2025; no disagreement with company.","Served as director since 2006, most recently as Compensation Committee Chair and on Nominating/Governance.","Former HHS Secretary and president of Morehouse School of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119537,"accession_number":"0001367644-25-000198","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).","Adjusted EBITDA $87.8M (38% margin); adjusted EPS $1.06; gross margin expanded 300bps to 54%.","Naloxone segment down 21% to $74.9M; MCM down 18% to $142.5M; Other Products up 91% to $57.5M.","FY2025 guidance raised: revenue $775-$835M (from $765-$835M), adjusted EBITDA $195-$210M (from $175-$200M).","Secured $56M ACAM2000, $52M CNJ-016, $30M CYFENDUS, $29M international MCM contracts in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":594200000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136106,"accession_number":"0001367644-25-000188","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.","Total 2025 projected sales for ACAM2000 and ancillary products exceed $120M from diverse customer base.","ACAM2000 is FDA-approved for smallpox (2007) and mpox (Aug 2024); also licensed in Canada, Australia, Singapore.","Modification exercises Option Year 6 under existing 10-year ASPR contract (75A50119C00071)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136105,"accession_number":"0001367644-25-000183","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).","Deliveries begin calendar 2025 and are scheduled to be completed by March 2026.","Follows a prior $50M modification in December 2024 for the same vaccine.","CYFENDUS received FDA approval in July 2023 as a two-dose post-exposure prophylaxis for adults 18-65."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136104,"accession_number":"0001367644-25-000179","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.","Adjusted EBITDA swung to $28.5M from ($10.1M) loss; adjusted gross margin expanded to 49% from 26%.","Naloxone revenue down 44% to $67.5M; Smallpox MCM up 127% to $40.6M; Anthrax MCM down 70%.","Raised FY2025 adjusted EBITDA guidance to $175-$200M (prev. $150-$200M); adjusted gross margin 50-52%.","Secured $65M multi-year NARCAN contract with Ontario Ministry of Health and $114.3M in contract modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":363100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153150,"accession_number":"0001367644-25-000153","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).","BAT is used to treat symptomatic botulism from exposure to botulinum neurotoxin serotypes A through G.","Supply supports U.S. government stockpile for military and civilian biodefense preparedness.","Paul Williams, SVP, noted the award reinforces Emergent's role in public health countermeasures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153149,"accession_number":"0001367644-25-000133","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court grants preliminary approval of $15M derivative suit settlement; final hearing Aug 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement covers five derivative actions alleging breach of fiduciary duty over Bayview vaccine manufacturing failures.","Insurers to pay $15M to Emergent; no admission of fault or liability by any defendant.","Board to adopt corporate governance reforms addressing manufacturing oversight and regulatory compliance.","Final approval hearing scheduled for August 6, 2025 in U.S. District Court for Maryland."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153148,"accession_number":"0001367644-25-000121","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.","Net income $68.0M ($1.19 diluted EPS) vs $9.0M prior year; adjusted EBITDA $77.6M, up 16%.","MCM Products segment revenues $156.6M (+1%), driven by 112% increase in Smallpox MCM to $106.4M.","Board authorized $50M share repurchase through March 2026; reaffirmed FY 2025 revenue guidance $750-$850M.","Recent deals: $20M BioThrax contract option, $16.7M BARDA collaboration, exclusive U.S./Canada rights to KLOXXADO."],"consensus_eps_estimate":null,"consensus_eps_actual":1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":222200000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153147,"accession_number":"0001367644-25-000114","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Emergent BioSolutions stockholders elect three Class I directors, ratify auditor, approve advisory compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held April 30, 2025; 36,140,808 shares (67% of outstanding) present.","Class I directors Keith Katkin, Ronald Richard, Kathryn Zoon each elected with >18M votes for.","Ernst & Young ratified as independent auditor for FY2025 with 34,773,959 for, 1,152,704 against.","Advisory vote on named executive officer compensation approved with 18,928,777 for, 3,537,501 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171934,"accession_number":"0001367644-25-000087","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions authorizes $50M share repurchase program through March 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $50 million of common stock on or before March 27, 2026.","CEO Joe Papa cites confidence in strategy, future outlook and cash generation as rationale.","Company had approximately 54.3 million shares outstanding as of December 31, 2024.","Repurchases may be made on open market or in private transactions; timing subject to market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171933,"accession_number":"0001367644-25-000083","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.","Syngene acquired assets and equipment of the Baltimore-Bayview drug substance manufacturing site.","Emergent retains rights to secure manufacturing services and capacity at the facility for future growth and pandemic response.","CEO Joe Papa says deal streamlines operations while maintaining flexibility; transaction supports multi-year turnaround."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171932,"accession_number":"0001367644-25-000054","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.","Emergent retains rights to secure manufacturing services and capacity at the facility for growth and pandemic response.","Emergent continues streamlined manufacturing network with facilities in Lansing, MI and Winnipeg, MB.","Bayview site received FDA 'No Action Indicated' (NAI) inspection outcome in March 2024.","CEO Joe Papa states sale advances multi-year transformation plan and turnaround phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171931,"accession_number":"0001367644-25-000019","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.","FY 2024 total revenue $1.04B (flat YoY); net loss $190.6M vs. $760.5M loss; adjusted EBITDA $183.1M vs. ($22.3M) loss.","FY 2025 guidance: revenue $750-850M; adjusted EBITDA $150-200M; segment adjusted gross margin 48-51%.","NARCAN sales fell 41% in Q4; Smallpox MCM sales surged 565% on ACAM2000 exports; Anthrax MCM down 71%.","Appointed CEO Joseph Papa; received ~$550M medical countermeasure awards; FDA approved ACAM2000 for mpox prevention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171930,"accession_number":"0001193125-25-007008","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions CEO presents at JPM conference; no material updates provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["President & CEO Joe Papa presented at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.","Slide deck furnished contains no specific financial metrics, guidance, or material corporate developments.","The event was a standard investor conference presentation with no new material disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171929,"accession_number":"0001367644-25-000010","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.","KLOXXADO complements existing OTC NARCAN 4 mg spray, offering higher-dose prescription option for opioid overdose reversal.","Hikma will continue manufacturing KLOXXADO; product will be integrated into Emergent's NARCANDirect distribution network.","CEO Joe Papa cites expanded product options to help reduce opioid overdose deaths and meet diverse patient and community needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171928,"accession_number":"0001367644-25-000004","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.","DoD exercised $20M option for BioThrax (Anthrax Vaccine Adsorbed); $7M delivered Dec 2024, balance in 2025.","Both modifications supplement existing IDIQ contracts with BARDA (HHSO100201600030C) and DoD (W911SR24D0001)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188930,"accession_number":"0001367644-24-000176","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.","Adjusted EBITDA surged 432% to $105.3M; company raises FY2024 revenue guidance to $1.065B-$1.125B.","Entered new $250M term loan with OHA Agency and $100M asset-backed loan with Wells Fargo.","Completed asset sales: RSDL product to SERB for $75M, Baltimore-Camden site for $35M, Canton warehouse for $7M.","Received $50M from Janssen contractual dispute resolution and $30M milestone from Bavarian Nordic."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":848900000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188929,"accession_number":"0001367644-24-000161","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Emergent Biosolutions grants CFO Lindahl 15,000 RSUs for strategic contributions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special one-time equity award of 15,000 restricted stock units approved on Oct 2, 2024.","Grant date is Oct 15, 2024; vests on first anniversary of grant.","Vesting subject to Mr. Lindahl's continued employment through the vesting date.","Award recognizes substantial contributions to recent strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188928,"accession_number":"0001193125-24-230710","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New asset-based revolving loan facility of up to $100M, maturing September 2029.","Cash balance of approximately $150M as of September 30, 2024.","ABL facility undrawn at closing; provides additional liquidity for transformation plan.","Facility follows prior $250M term loan refinancing with Oak Hill Advisors in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205406,"accession_number":"0001367644-24-000158","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Emergent BioSolutions issues 1.1M shares to lenders, sets warrant exercise prices at $9.88 and $15.72","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,113,338 shares of common stock at ~$8.98 per share to lenders under Term Loan Agreement.","Series I Warrants for 1M shares at $9.8802 exercise price; Series II Warrants for 1.5M shares at $15.7185.","No proceeds from share issuance; company will receive proceeds upon exercise of warrants.","Warrants expire August 30, 2029, unless exercised earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205405,"accession_number":"0001193125-24-211548","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions closes $250M term loan with Oak Hill Advisors; extends maturity to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$250M term loan drawn in full, matures August 2029; used to repay existing senior term loan due May 2025 and terminate revolver.","Issued warrants for 2.5M shares at 110% and 175% of 30-day VWAP; agreed to issue $10M in common stock at VWAP.","Interest at SOFR+8.25% or Base Rate+7.25%; default rate +2%; covenants include $75M minimum liquidity and leverage ratio tests.","New facility expected to reduce net debt by >$200M in 2024; management cites greater operational flexibility for turnaround.","Oak Hill Advisors serves as lead agent; company to participate in Wells Fargo and H.C. Wainwright conferences in September."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205404,"accession_number":"0001367644-24-000155","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions gets FDA approval for ACAM2000 mpox indication","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved sBLA for ACAM2000 to prevent mpox in high-risk individuals based on animal study safety/efficacy data.","ACAM2000 is a single-dose, percutaneously administered smallpox vaccine first approved in 2007.","Emergent will donate 50,000 doses for potential deployment across impacted Central African countries.","Company filed Expression of Interest with WHO for Emergency Use Listing amid mpox outbreak."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205403,"accession_number":"0001367644-24-000152","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Emergent BioSciences closes sale of Baltimore-Camden facility to Bora for $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold drug product facility in Baltimore-Camden to affiliate of Bora Pharmaceuticals (TWSE:6472) for ~$30M at closing.","Bora acquired all assets, equipment, and workforce associated with the 87,000 sq ft facility.","CEO Joe Papa says sale is a step in multi-year plan to stabilize, improve profitability, and reduce debt.","Truist Securities and Covington & Burling advised Emergent on the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205402,"accession_number":"0001367644-24-000142","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.","Bioservices services revenue $64.5M (+144% YoY) including $50M Janssen arbitration settlement; cost $211.6M with asset write-down.","Updated FY2024: total revenue $1,050-$1,125M (raised); net loss $(314)-$(274)M (wider); adj. EBITDA $140-$180M (raised).","Asset sales: $30M Baltimore-Camden site sale expected Q3 2024; $75M from RSDL sale to SERB; $50M Janssen dispute resolution.","Impairment $27.2M in Q2 vs $306.7M a year ago, related to Bayview and Rockville asset groups."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":555100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205401,"accession_number":"0001367644-24-000134","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions sells RSDL decontamination kit to SERB for $75M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash purchase price of $75M at closing; additional $5M milestone payment for component sourcing.","Sale includes Hattiesburg, MS manufacturing facility, IP, inventory, and marketing authorizations; employees to join SERB.","Emergent's Winnipeg facility will manufacture bulk lotion for SERB under long-term supply agreement.","SERB assumes existing RSDL supply contract with U.S. Department of Defense.","Net proceeds expected to reduce debt by >$150M, targeting elimination of Junior Capital Raise requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205400,"accession_number":"0001367644-24-000130","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Emergent BioSolutions EVP, General Counsel and Corporate Secretary Jennifer Fox resigns effective August 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Fox resigns as EVP External Affairs, General Counsel and Corporate Secretary to pursue an external opportunity.","Her resignation is effective August 16, 2024; she will continue in her role until that date.","No successor has been announced; CFO Richard S. Lindahl remains in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205399,"accession_number":"0001367644-24-000125","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Emergent BioSolutions grants 15,000 RSUs to EVP Jennifer Fox for strategic contributions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jennifer Fox, EVP External Affairs, General Counsel, and Corporate Secretary, receives 15,000 restricted stock units.","Award vests on first anniversary of grant date, contingent on continued employment.","Special one-time discretionary award approved by Compensation Committee on July 11, 2024.","Award recognizes Fox's substantial contributions to executing recent strategic initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205398,"accession_number":"0001367644-24-000118","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.","Settlement resolves all claims and arbitration related to MSA for Ad26.COV2-S vaccine.","Parties exchange broad releases covering affiliates, officers, and directors.","Ends previously disclosed arbitration between Emergent and Janssen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205397,"accession_number":"0001367644-24-000116","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.","Modification 17 for CYFENDUS anthrax vaccine valued at $30.0M for delivery this year.","Two options totaling $122.9M for VIGIV (smallpox complication) and BAT (botulism antitoxin) into early 2025.","All awards from ASPR under existing 10-year contracts; reaffirms Emergent as trusted biodefense partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222310,"accession_number":"0001367644-24-000112","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.","Approximately 350 Emergent employees expected to join Bora as part of the transaction.","Deal is part of multi-year plan to reduce debt, improve profitability, and streamline manufacturing to Lansing and Winnipeg.","Closing expected in Q3 2024, subject to customary conditions; Truist Securities and Covington & Burling advised Emergent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222309,"accession_number":"0001367644-24-000093","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.","Elected directors DeGolyer, Fowler, White; say-on-pay passed; EY ratified as auditor.","Launched OTC NARCAN Nasal Spray; FDA approved two-dose anthrax vaccine CYFENDUS.","Won $379.6M DoD contract for RSDL kits and $235.8M contract for BioThrax.","Cut ~$240M annualized OpEx; extended secured credit facility to May 2025; divested Travel Health up to $380M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222308,"accession_number":"0001367644-24-000060","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.","Adjusted EBITDA $66.9M vs $(101.5)M; adjusted EPS $0.59 vs $(3.26).","FY2024 guidance raised: total rev $1.0-1.1B, adj EBITDA $125-175M, adj net loss $(65)-(15)M.","ASPR contract modification reduces minimum purchase from 9M to 3.5M doses annually for Option Years 5-9; max contract value revised to $1.4B.","NARCAN sales up 18% to $118.5M; MCM segment gross margin improved to 60%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":300400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222307,"accession_number":"0001367644-24-000058","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.","Closes Baltimore-Bayview Drug Substance and Rockville Drug Product manufacturing facilities.","Estimated charges of $18-21M primarily in H2 2024; expects annualized savings of ~$80M.","Operations concentrated at Winnipeg and Lansing; new Chief Science Officer role created.","Q1 2024 earnings to be reported May 1; also filed amendment to credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222306,"accession_number":"0001367644-24-000055","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Emergent BioSolutions amends credit facility; revolver cut to $270M, interest margins raised","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving commitments reduce to $270M through July 30, then $225M, and $200M after Oct 31, 2024.","Interest margins increase: Base Rate loans from 5% to 7%, SOFR/Eurocurrency from 6.5% to 8.5%.","Company must raise at least $85M in equity or unsecured debt by July 31, 2024 (may be reduced by asset sale proceeds).","100% of net proceeds from certain dispositions must prepay revolver (up to $85M); excess applies to term loan.","New monthly minimum EBITDA, maximum capex, and minimum liquidity covenants added through 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222305,"accession_number":"0001367644-24-000053","cik":1367644,"company_name":"Emergent BioSolutions Inc.","ticker":"EBS","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emergent BioSolutions awards $1.45M in additional retention bonuses to four top executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Richard Lindahl receives $399,753; GC Jennifer Fox $380,250; EVP Quality Coleen Glessner $373,761; SVP Products Paul Williams $292,501.","Bonuses payable by Dec 31, 2024, subject to continued employment; acceleration possible upon transaction support agreement with debt holders.","Clawback: executives must repay bonuses if they voluntarily leave or are terminated for cause before retention period ends.","Retention period ends earlier of July 26, 2024 (initial bonuses), Dec 31, 2024 (additional), or 30 days after change of control or bankruptcy exit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":465914572.94666666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}